## In This Issue
Highlighted research articles ........................................ 591

## News in Brief
Important news stories affecting the community ....................... 594

## Q&A: Ashok Venkitaraman on “Undruggable” Targets ............ 597
Second Chances for Shelved Compounds ............................. 598

## Research Watch
Selected highlights of recent articles of exceptional significance from the cancer literature ............................................. 599

## Online
For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

## Views
In The Spotlight

- The New Kid on the Block: RET in Lung Cancer ............... 604
  J.F. Gainor and A.T. Shaw
  See article, p. 630

- FGFR Fusions in the Driver’s Seat ............................... 607
  A.J. Sabnis and T.G. Bivona
  See article, p. 636

- Extending the Convergence of Canonical WNT Signaling and Classic Cancer Pathways for Treatment of Malignant Peripheral Nerve Sheath Tumors .......... 610
  K.M. Reilly
  See article, p. 674

- A New Alpha in Line Between KRAS and NF-κB Activation? .... 613
  C. Pak and S. Miyamoto
  See article, p. 690

## Reviews
Illuminating Cancer Systems with Genetically Engineered Mouse Models and Coupled Luciferase Reporters In Vivo .................. 616
B. Kocher and D. Piwnica-Worms

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas ................................. 630

Identification of Targetable FGFR Gene Fusions in Diverse Cancers ........................................ 636

Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor ..................... 648

## News in Depth
For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer .... 658
Précis: MET amplification underlies acquired resistance to cetuximab or panitumumab in colorectal cancers that have not developed secondary KRAS mutations.

Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance ............... 674

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org. Online-only News stories include the following:
• Next-Generation Screening Goes National in UK
• Anti-HER2 Drugs May Benefit Some Lung Cancer Patients
• Outreach Cuts Disparities in Colorectal Cancer Deaths
• Debating Drug Approval Decisions
• FDA Struggles with Spending Uncertainties
• Lighting Up Discussion on Tobacco Use

ON THE COVER
Killian and colleagues found that gastrointestinal stromal tumors (GIST) with mutations in succinate dehydrogenase (SDH) complex genes exhibited a distinct methylation signature relative to the profile of KIT-mutant tumors and normal reference tissues. This methyl-divergent profile was distinguished by increased global DNA hypermethylation, particularly at DNase hypersensitive sites, and was also present in other SDH-mutant tumor lineages, including paraganglioma and pheochromocytoma, supporting the oncogenotype dependence of this signature. In addition, a similarly perturbed methylation profile was detected in gliomas harboring mutations in another Krebs cycle enzyme, isocitrate dehydrogenase (IDH). These findings identify a strong association between the mitochondrial Krebs cycle and cancer epigenomic reprogramming. For details, please see the article by Killian and colleagues on page 648.